Canopy Growth Corp (CGC)vsZoetis Inc (ZTS)
CGC
Canopy Growth Corp
$0.89
-0.53%
HEALTHCARE · Cap: $405.86M
ZTS
Zoetis Inc
$77.93
+0.54%
HEALTHCARE · Cap: $32.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 3249% more annual revenue ($9.53B vs $284.60M). ZTS leads profitability with a 28.0% profit margin vs -92.4%. ZTS earns a higher WallStSmart Score of 66/100 (B-).
CGC
Avoid34
out of 100
Grade: F
ZTS
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CGC.
Margin of Safety
+10.8%
Fair Value
$144.23
Current Price
$77.93
$66.30 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 82 in profit
Strong operational efficiency at 36.6%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -41.0% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Trading at 9.9x book value
2.9% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : CGC
The strongest argument for CGC centers on Price/Book.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.0% and operating margin at 36.6%.
Bear Case : CGC
The primary concerns for CGC are EPS Growth, Market Cap, Return on Equity.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.86 is elevated, increasing financial risk.
Key Dynamics to Monitor
CGC profiles as a turnaround stock while ZTS is a value play — different risk/reward profiles.
CGC carries more volatility with a beta of 2.42 — expect wider price swings.
CGC is growing revenue faster at 9.6% — sustainability is the question.
ZTS generates stronger free cash flow (291M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (66/100 vs 34/100), backed by strong 28.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Canopy Growth Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Canopy Growth Corporation is engaged in the production, distribution and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. The company is headquartered in Smiths Falls, Canada.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?